Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report)’s stock price hit a new 52-week high during trading on Tuesday. The stock traded as high as $21.25 and last traded at $21.0340, with a volume of 13,031 shares. The stock had previously closed at $21.02.
Analysts Set New Price Targets
A number of equities research analysts have weighed in on the company. Oppenheimer assumed coverage on Amneal Pharmaceuticals in a report on Wednesday, September 23rd. They set an “outperform” rating and a $27.00 price objective on the stock. Barclays lifted their price objective on shares of Amneal Pharmaceuticals from $16.00 to $20.00 and gave the stock an “overweight” rating in a research report on Thursday, September 17th. UBS Group reaffirmed a “buy” rating on shares of Amneal Pharmaceuticals in a research note on Thursday, October 1st. Weiss Ratings raised Amneal Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, October 8th. Finally, The Goldman Sachs Group reissued a “buy” rating and issued a $21.00 price target on shares of Amneal Pharmaceuticals in a research report on Friday, July 31st. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $21.25.
Get Our Latest Stock Analysis on AMRX
Amneal Pharmaceuticals Stock Up 1.0%
The business has a fifty day moving average price of $18.81 and a two-hundred day moving average price of $15.54. The firm has a market capitalization of $6.78 billion, a price-to-earnings ratio of 43.40, a price-to-earnings-growth ratio of 2.38 and a beta of 1.22. The company has a debt-to-equity ratio of 77.65, a current ratio of 2.20 and a quick ratio of 1.44.
Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) last announced its earnings results on Thursday, July 30th. The company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.06. The firm had revenue of $796.20 million for the quarter. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. On average, equities analysts expect that Amneal Pharmaceuticals, Inc. will post 0.95 earnings per share for the current year.
Insider Buying and Selling at Amneal Pharmaceuticals
In other news, Director John Kiely sold 50,000 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $17.64, for a total transaction of $882,000.00. Following the transaction, the director directly owned 210,252 shares of the company’s stock, valued at $3,708,845.28. This represents a 19.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Nikita Shah sold 146,403 shares of Amneal Pharmaceuticals stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $17.51, for a total transaction of $2,563,516.53. Following the completion of the transaction, the executive vice president owned 253,390 shares of the company’s stock, valued at $4,436,858.90. The trade was a 36.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 413,016 shares of company stock worth $7,216,567. Insiders own 17.30% of the company’s stock.
Institutional Investors Weigh In On Amneal Pharmaceuticals
Large investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC boosted its holdings in shares of Amneal Pharmaceuticals by 72.2% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 2,549,572 shares of the company’s stock valued at $32,405,000 after buying an additional 1,069,400 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in Amneal Pharmaceuticals during the second quarter worth about $17,573,000. Principal Financial Group Inc. grew its position in shares of Amneal Pharmaceuticals by 527.9% during the first quarter. Principal Financial Group Inc. now owns 972,529 shares of the company’s stock worth $12,089,000 after buying an additional 817,652 shares in the last quarter. Congress Asset Management Co. boosted its holdings in Amneal Pharmaceuticals by 94.7% in the third quarter. Congress Asset Management Co. now owns 1,524,355 shares of the company’s stock valued at $30,701,000 after purchasing an additional 741,577 shares in the last quarter. Finally, Quartz Partners LLC acquired a new stake in shares of Amneal Pharmaceuticals in the first quarter valued at approximately $5,559,000. Institutional investors own 31.82% of the company’s stock.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include oral, injectable and inhaled medications, as well as complex dosage forms and other products designed to address areas where manufacturing or formulation requirements can be more challenging.
The company’s generics business offers medicines across a range of therapeutic categories, including central nervous system, cardiovascular, gastrointestinal, anti-infective and other treatments.
Read More
- Five stocks we like better than Amneal Pharmaceuticals
- Intel’s $155 Price Target Raises a Bigger Question About Its Turnaround Potential
- AST SpaceMobile Faces Launch Risks as SpaceX Raises the Competitive Stakes
- GXO Logistics Is Turning Warehouse Robots Into a Growth Strategy
- A Solid Margin Story Means the Sell-Off in DECK May Be Overdone
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
